In addition, pulmonary nodules harboring KRAS_MT exhibited significantly higher IFN-gamma signatures compared to those with EGFR_MT (p < 0.05) (Fig. 3a and Supplementary Table 4), implying that tumors harboring EGFR_MT might exhibit reduced capacity to suppress tumor proliferation and antigen presentation efficiency when compared to tumors with KRAS_MT, as indicated by Hastings et al.23. This evidence concerns the gene IFNG and neoplasm.